Sangeeta N. Bhatia - 08 Aug 2024 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Role
Director
Signature
/s/ Christiana Stevenson, Attorney-in-Fact
Issuer symbol
VRTX
Transactions as of
08 Aug 2024
Net transactions value
-$405,107
Form type
4
Filing time
12 Aug 2024, 16:08:21 UTC
Previous filing
03 May 2024
Next filing
04 Sep 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Options Exercise $197,340 +1,292 +29% $152.74 5,727 08 Aug 2024 Direct
transaction VRTX Common Stock Sale $602,447 -1,292 -23% $466.29 4,435 08 Aug 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VRTX Stock Option (Right to Buy) Options Exercise $0 -1,292 -67% $0.000000 646 08 Aug 2024 Common Stock 1,292 $152.74 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Transaction made pursuant to Dr. Bhatia's company approved trading plan under Rule 10b5-1, which was entered into on 05/09/2024.
F2 Fully vested.